Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. enrollment expected to commence in the first part of 2025 Phase 3 tumor HI study expected to commence in the first half of 2025 REDWOOD CITY, Calif., November 07, 2024 – Rezolute, Inc. (Nasdaq: RZLT ...